Eaton Corporation plc vs Viatris Inc — how do they compare? Eaton Corporation plc trades at $429.65 (market cap $164.88B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Eaton Corporation plc is far larger — about 8.2× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Eaton Corporation plc for 31 Days and Viatris Inc for 57 Days on average.
| ETN | VTRS | |
|---|---|---|
Market Cap | $164.88B | $20.03B |
Volume | 2,535,086 | 14,109,977 |
Sector | Industrials | Health |
52-Week High | $459.96 | $18.27 |
52-Week Low | $315.82 | $9.74 |
Typical Hold Time | 31 Days | 57 Days |
Enterprise Value | $185.51B | $32.15B |
Dividend Yield | 1.04% | 2.75% |
Signals from Pluang's Aura AI — not financial advice
Eaton Corporation (ETN) trades at $429.65, down 0.39% on the day, with technical indicators showing a bearish bias despite recent earnings beats. The company maintains strong fundamentals with 12.75% net income margin and 19.71% ROE, supported by strategic acquisitions in data center and aerospace markets. Analyst consensus remains strongly bullish with a $502.38 price target, representing 17% upside potential from current levels.
ETN's outlook remains positive driven by data center demand and grid modernization trends, though elevated valuation multiples (P/E 43.23) and bearish technical signals warrant caution. The stock faces execution risks from recent acquisitions and competitive pressure in the electrical equipment sector, but strong institutional support and consistent earnings performance support the bullish analyst stance.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.
The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →